Recital 4, Regulation (EU) 2024/2684

In forcesince 2 Feb 2024

Upon request from the Commission, the Authority issued a scientific opinion on 18 July 2023 on the nutritional safety and suitability of that infant and follow-on formula [EFSA NDA Panel (EFSA Panel on Nutrition, Novel Foods and Food Allergens), 2023. Nutritional safety and suitability of a specific protein hydrolysate derived from whey protein concentrate and used in an infant formula and follow-on formula manufactured from hydrolysed protein by FrieslandCampina Nederland B.V. EFSA Journal 2023;21(7):8063.]. In that opinion, the Authority concluded that the protein hydrolysate in question is a nutritionally safe and suitable protein source for use in infant and follow-on formula, as long as the formula in which it is used contains a minimum of 0,57 g/100 kJ (2,4 g/100 kcal) protein and complies with the other compositional criteria set out in Delegated Regulation (EU) 2016/127 and with the amino acid pattern contained in Section A of Annex III to that Regulation.